Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics, Inc. (TVTX) reported that Chief Executive Officer and director Eric M. Dube exercised employee stock options for a total of 400,000 shares of common stock at an exercise price of $23.34 per share on September 15–17, 2026, and sold 400,000 shares of common stock in open-market transactions on the same dates. The sales were made under a written trading plan adopted on June 16, 2026, that meets Rule 10b5-1(c) requirements, and the options exercised were fully vested and exercisable.
Travere Therapeutics, Inc. (TVTX) reports that its chief financial officer, Christopher R. Cline, exercised employee stock options for 20,000 shares of common stock at an exercise price of $17.44 per share on September 15, 2026, and the corresponding option position was reduced to zero. On the same date, he sold an aggregate of 50,508 shares of common stock in multiple open-market transactions at weighted average prices between approximately $62.00 and $65.31 per share. The sales were made pursuant to a Rule 10b5-1(c) trading plan adopted on June 16, 2026.
Travere Therapeutics, Inc. (TVTX) reported that Sandra Calvin, its SVP, Chief Accounting Officer, exercised employee stock options for a total of 5,375 shares of common stock on September 15, 2026 at strike prices of $27.50, $22.40, and $20.46 per share, and on the same date sold 5,375 shares of common stock in multiple transactions at weighted average prices between about $62.14 and $63.66. The sales were made pursuant to a Rule 10b5-1(c) trading plan adopted on June 16, 2026.
Travere Therapeutics, Inc. (TVTX) is the issuer for a planned resale of common stock reported by Eric Dube under Rule 144. The notice covers up to 108,493 shares of common stock to be sold through Morgan Stanley Smith Barney LLC, based on an aggregate market value of $6,887,135.64 and referencing 94,261,082 shares outstanding on September 17, 2026.
The shares to be sold are tied to an exercise of stock options on September 17, 2026, for cash. The filing also lists prior 10b5-1 sales of Travere common stock for Eric Dube over the past three months.
Travere Therapeutics, Inc. (TVTX) insider Peter Heerma, an officer, filed a notice of proposed sale of common stock under Rule 144. The notice lists a planned sale of 8,282 shares of common stock on September 17, 2026, following option exercises for cash with the issuer.
The filing also lists prior Rule 10b5-1 plan sales of Travere Therapeutics common stock during the preceding three months, reflecting significant recent disposition activity by the same insider.
Travere Therapeutics, Inc. (TVTX) is the issuer in a notice that officer William Rote intends to sell 112,850 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $7,054,253.50, as of a proposed sale date of September 16, 2026 on NASDAQ.
The shares to be sold were acquired from the issuer on September 16, 2026 via an exercise of stock options paid in cash. The notice also reports that during the prior three months, a separate Rule 10b5-1 sales program for E. Rote involved the sale of 96,198 shares of common stock on September 15, 2026 for aggregate proceeds of $5,988,758.39.
Travere Therapeutics, Inc. (TVTX) officer Peter Heerma filed a notice of proposed sale of company stock under Rule 144. The notice covers 172,717 shares of common stock, to be sold through Morgan Stanley Smith Barney, with an indicated aggregate market value of $10,796,539.67 as of September 16, 2026. Travere reports 94,261,082 shares of common stock outstanding. The securities to be sold were acquired on September 16, 2026 through an exercise of stock options for cash. In the prior three months, a separate sale of 102,190 shares of common stock for $6,362,824.52 on September 15, 2026 is also listed for Heerma under a 10b5-1 plan.
Travere Therapeutics, Inc. (TVTX) is the issuer for a planned sale of its common stock reported on behalf of Eric Dube under Rule 144. The notice covers the potential sale of 195,841 shares of common stock on September 16, 2026, in connection with an exercise of stock options for cash.
The securities are held through Morgan Stanley Smith Barney LLC Executive Financial Services and are listed on NASDAQ. Over the prior three months, a separate Rule 10b5-1 transaction on September 15, 2026 involved 95,666 shares of common stock at an aggregate sale price of $5,955,801.63.
Travere Therapeutics, Inc. (TVTX) has a notice under Rule 144 indicating that officer Sandra Calvin may sell up to 5,375 shares of Travere common stock. The shares are associated with an exercise of stock options for cash and are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate value of $353,621.25 as of September 15, 2026 on NASDAQ.
Travere Therapeutics, Inc. (TVTX) officer Christopher Cline filed a notice of proposed sale of Travere common stock under Rule 144. The filing contemplates the sale of up to 50,508 shares of common stock through Morgan Stanley Smith Barney LLC on or after September 15, 2026.
The shares to be sold include 20,000 shares related to an Exercise of Stock Options dated September 15, 2026 and 30,508 shares acquired from Restricted Stock Units granted May 9, 2020 and vesting through September 1, 2026. The notice also reports a prior sale of 642 shares on September 2, 2026.